Nivalis Therapeutics Inc. (NVLS) Plummeted To A New Low After Study Failed

Nivalis Therapeutics Inc. (NVLS) announced after the bell Monday that its Phase 2 trial of two doses of cavosonstat, 200 mg and 400 mg, failed to achieve the primary endpoint.

from RTT - Before the Bell http://ift.tt/2fQpgb1
via IFTTT